Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 100 versus FENTANYL CITRATE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 100 versus FENTANYL CITRATE PRESERVATIVE FREE.
FENTANYL-100 vs FENTANYL CITRATE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein coupled receptor signaling (inhibition of adenylate cyclase, modulation of ion channels), leading to increased potassium conductance and decreased calcium influx, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Synthetic opioid agonist; primarily binds to mu-opioid receptors in the CNS, modulating nociceptive pathways and producing analgesia, sedation, and euphoria.
100 mcg intravenously every 1-2 hours as needed for pain; or 100 mcg intramuscularly every 1-2 hours; transdermal patch: 12-100 mcg/hour applied every 72 hours; buccal tablet: 100-200 mcg as a single dose for breakthrough pain.
Initial: 50-100 mcg IV every 2-5 minutes as needed for pain. For anesthesia: 2-50 mcg/kg IV bolus, then 0.7-10 mcg/kg/hr infusion.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours in adults; prolonged in elderly, hepatic impairment, or continuous infusion (due to redistribution).
Terminal elimination half-life is approximately 2–4 hours in healthy adults, but may be prolonged to 4–12 hours in elderly, critically ill, or obese patients due to increased volume of distribution and decreased clearance. Context: Duration of action after a single bolus is relatively short due to redistribution, but accumulation can occur with repeated doses or infusions, leading to prolonged effects.
Primarily hepatic metabolism to inactive metabolites (norfentanyl, etc.); ~75% excreted in urine as metabolites, ~9% in feces, <10% unchanged in urine.
Primarily hepatic metabolism via CYP3A4, with approximately 75% of the dose excreted in urine as metabolites (primarily norfentanyl) and <10% as unchanged fentanyl. About 9% is excreted in feces. Minimal biliary excretion.
Category D/X
Category D/X
Opioid Agonist
Opioid Agonist